Transcend Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 16 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.53 M
- Satisfied Charges ₹ 3.80 M
- Revenue Growth 27.88%
- Profit Growth 198.71%
- Ebitda 23.96%
- Net Worth 21.42%
- Total Assets 10.64%
About Transcend Therapeutics
Transcend Therapeutics Private Limited (TTPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 June 2008 and has a history of 16 years and seven months. Its registered office is in Kanchipuram, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.53 M. The company has closed loans amounting to ₹3.80 M, as per Ministry of Corporate Affairs (MCA) records.
Renuka Chandrasekaran and Meena Chandrashekar serve as directors at the Company.
Company Details
-
Location
Kanchipuram, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230TN2008PTC068018
-
Company No.
068018
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Jun 2008
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Transcend Therapeutics?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Renuka Chandrasekaran
|
Director | 04-Jun-2008 | Current |
|
Meena Chandrashekar
|
Director | 01-Jun-2024 | Current |
Financial Performance of Transcend Therapeutics.
Transcend Therapeutics Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 27.88% increase. The company also saw a substantial improvement in profitability, with a 198.71% increase in profit. The company's net worth Soared by an impressive increase of 21.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Transcend Therapeutics?
In 2019, Transcend Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.53 M
₹3.80 M
Charges Breakdown by Lending Institutions
- Others : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Jul 2023 | Others | ₹1.23 M | Open |
| 20 May 2023 | Others | ₹1.30 M | Open |
| 28 Jun 2017 | Others | ₹3.80 M | Satisfied |
How Many Employees Work at Transcend Therapeutics?
Unlock and access historical data on people associated with Transcend Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Transcend Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Transcend Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
